Flerie AB (publ) (STO:FLERIE)
21.00
+0.30 (1.45%)
Jul 24, 2026, 3:58 PM CET
Flerie AB Revenue
Flerie AB had revenue of -79.90M SEK in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to -782.90M. In the year 2025, Flerie AB had annual revenue of -714.60M.
Revenue (ttm)
-782.90M
Revenue Growth
-3.85%
P/S Ratio
-320.47
Revenue / Employee
-2.80M
Employees
2
Market Cap
1.79B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | -714.60M | -596.70M | - |
| Dec 31, 2024 | -117.90M | 400.70M | - |
| Dec 31, 2023 | -518.60M | -569.38M | - |
| Dec 31, 2022 | 50.78M | 38.19M | 303.43% |
| Dec 31, 2021 | 12.59M | 12.24M | 3,537.86% |
| Dec 31, 2020 | 346.00K | 319.00K | 1,181.48% |
| Dec 31, 2019 | 27.00K | -563.00K | -95.42% |
| Dec 31, 2018 | 590.00K | -76.00K | -11.41% |
| Dec 31, 2017 | 666.00K | 2.01M | - |
| Dec 31, 2016 | -1.34M | -1.31M | - |
| Dec 31, 2015 | -31.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 429.29M |
| BioInvent International AB | 217.86M |
| Hansa Biopharma AB | 190.49M |
| Genovis AB (publ.) | 131.09M |
| Egetis Therapeutics AB | 63.10M |
| Medivir AB | 9.01M |
| Vicore Pharma Holding AB | 3.53M |
| Xspray Pharma AB | 2.47M |
Flerie AB News
- 15 days ago - Flerie AB Quarterly report: Q2 2026 - Filings
- 3 months ago - Flerie AB Earnings Call Transcript: Q1 2026 - Transcripts
- 3 months ago - Flerie AB Quarterly report: Q1 2026 - Filings
- 3 months ago - Flerie AB Slides: Q1 2026 - Filings
- 6 months ago - Flerie AB Earnings Call Transcript: Q4 2025 - Transcripts
- 6 months ago - Flerie AB Annual report: Q4 2025 - Filings
- 6 months ago - Flerie AB Quarterly report: Q4 2025 - Filings
- 9 months ago - Flerie AB Earnings Call Transcript: Q3 2025 - Transcripts